ストックスクリーナーアプリを入手
124.09
1.37%
-1.7505
前日終値:
$125.84
開ける：
$125.885
24時間の取引高:
2.62M
Relative Volume:
0.37
時価総額：
$154.02B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
19.22
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
-0.92%
1か月 パフォーマンス:
+3.61%
6か月 パフォーマンス:
+12.75%
1年 パフォーマンス:
+34.07%
1日の値動き範囲:
$123.62
$126.23
1週間の範囲:
$123.62
$128.16
52週間の値動き範囲:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
124.14 | 156.13B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,058.81 | 962.57B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.28 | 498.53B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.62 | 402.43B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
129.25 | 250.21B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
102.26 | 260.19B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
News Is Out hosting Gilead’s Choose U World AIDS Day panel - Dallas Voice
Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewswire Inc.
Gifford Fong Associates Sells 25,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz - The National Law Review
Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver - Insider Monkey
West Family Investments Inc. Has $1.35 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
New York State Common Retirement Fund Sells 15,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Scotia Capital Inc. Sells 17,090 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Level Four Advisory Services LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Laurel Wealth Advisors LLC Acquires 6,593 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Edgewood Management LLC Sells 2,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - Insider Monkey
Skandinaviska Enskilda Banken AB publ Acquires 252,108 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
State Board of Administration of Florida Retirement System Purchases 15,800 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Quadrant Capital Group LLC Has $3.82 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative? - Yahoo Finance
Is Gilead Sciences a Bargain After 40% Share Price Surge and Pipeline Updates? - Yahoo Finance
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Some CAR-Ts Are Thriving While Others Are Falling Behind. Why? - Citeline News & Insights
Vinva Investment Management Ltd Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Johnson Financial Group Inc. Buys 4,239 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Korea Investment CORP Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Kiltearn Partners LLP Sells 11,600 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Steward Partners Investment Advisory LLC Sells 2,152 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILEAD FOUNDATION COMMITS OVER $3 MILLION TO ADDRESS FOOD INSECURITY AS COMMUNITIES FACE RISING HEALTH RISKS - Gaye Magazine
Gilead Plans 800K-SF Expansion at Foster City Campus - Hoodline
Te Ahumairangi Investment Management Ltd Purchases 9,624 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - The Business Journals
Northwest & Ethical Investments L.P. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences Inc. stock oversold or undervaluedMarket Growth Report & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Rhenman & Partners Asset Management AB Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Acquires Shares of 20,074 Gilead Sciences, Inc. $GILD - MarketBeat
Vera Therapeutics appoints former Gilead executive to board By Investing.com - Investing.com South Africa
Dir Kramer Files To Sell 5,611 Of Gilead Sciences Inc [GILD] - TradingView
Vera Therapeutics appoints former Gilead executive to board - Investing.com
Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact - Citeline News & Insights
Verity & Verity LLC Sells 43,792 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Oak Associates Ltd. OH Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jefferies Financial Group Inc. Has $7.06 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Escalator: Gilead Sciences, Medtronic, Labcorp and more - Medical Marketing and Media
CreativeOne Wealth LLC Has $3.52 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead acquires Sprint’s pre-clinical TREX1 cancer programme - PharmiWeb.com
Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m - Pharmaceutical Technology
Truist Financial Initiates Coverage on Gilead Sciences (NASDAQ:GILD) - MarketBeat
Gilead scoops up a preclinical cancer program - BioPharma Dive
Bob Allen joins Gilead’s public affairs team - Medical Marketing and Media
Gilead Sciences stock rating reiterated at Outperform by BMO Capital - Investing.com
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
0.07%
大文字化:
|
ボリューム (24 時間):